{"entity":{"id":"nct05872347","kind":"trial","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","aka":[],"tldr":"A phase 2 trial of SPH4336 in brain and spinal cord tumours, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.","summary":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. is a phase 2 interventional study registered as NCT05872347 by Shanghai Pharmaceuticals Holding Co., Ltd, with 52 participants planned, started 2023-09-19 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH4336 Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05872347","url":"https://clinicaltrials.gov/study/NCT05872347"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["sph4336"],"companies":["genfleet"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05872347","phase":"2","setting":"A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","enrolled":52,"outcomes":[]},"route":"/trials/nct05872347/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"sph4336","kind":"drug","name":"SPH4336","route":"/drugs/sph4336/"}],"company":[{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/"}]}}